Spots Global Cancer Trial Database for metastatic castration resistant prostate cancer (mcrpc)
Every month we try and update this database with for metastatic castration resistant prostate cancer (mcrpc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. | NCT02933801 | Prostate Cancer... Prostate Cancer | ODM-201 Placebo | 18 Years - | Swiss Group for Clinical Cancer Research | |
| ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. | NCT02933801 | Prostate Cancer... Prostate Cancer | ODM-201 Placebo | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | NCT05701007 | Metastatic Cast... Metastatic Cast... | abiraterone enzalutamide docetaxel apalutamide cabazitaxel Radium-223 Lutetium-177 degarelix goserelin leuprorelin triptorelin | 18 Years - | Pfizer | |
| ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. | NCT02933801 | Prostate Cancer... Prostate Cancer | ODM-201 Placebo | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | NCT03549000 | Non-small Cell ... Triple Negative... Pancreatic Duct... Colorectal Canc... Ovarian Cancer Renal Cell Carc... Metastatic Cast... | NZV930 PDR001 NIR178 | 18 Years - | Novartis | |
| Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide | NCT02130947 | Metastatic Cast... | Exercise | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer | |
| Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer | NCT03724747 | Metastatic Cast... | BAY2315497 Inje... Darolutamide(BA... | 18 Years - | Bayer | |
| 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer | NCT03874884 | Metastatic Cast... | Olaparib 177Lu-PSMA | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer | NCT05425862 | Metastatic Cast... | Pidnarulex Talazoparib | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA) | NCT05208229 | Metastatic Cast... | WB-MRI | - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer | |
| EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo) | NCT04516161 | Metastatic Cast... | Radium-223 dich... | 18 Years - | Bayer | |
| Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer | NCT05425862 | Metastatic Cast... | Pidnarulex Talazoparib | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer | |
| The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA) | NCT05208229 | Metastatic Cast... | WB-MRI | - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials | NCT06141993 | Prostate Cancer Prostate Adenoc... Prostate Cancer... Castration-resi... | 18 Years - | Duke University | ||
| EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo) | NCT04516161 | Metastatic Cast... | Radium-223 dich... | 18 Years - | Bayer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
